World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ClinicalTrials.gov
Last refreshed on: 12 December 2020
Main ID:  NCT01076374
Date of registration: 24/02/2010
Prospective Registration: No
Primary sponsor: Medtronic
Public title: MEDTRONIC ADAPTA, VERSA AND SENSIA nEw3 POST APPROVAL STUDY
Scientific title: Medtronic Adapta/Versa/Sensia Long Term Reliability Study
Date of first enrolment: July 2008
Target sample size: 2927
Recruitment status: Completed
URL:  https://clinicaltrials.gov/show/NCT01076374
Study type:  Observational
Study design:   
Phase: 
Countries of recruitment
Australia Austria Belgium Canada Denmark Former Serbia and Montenegro France Germany
Italy Netherlands Serbia Spain Sweden Switzerland United States
Contacts
Name:     nEw3 PAS Clinical Trial Leader
Address: 
Telephone:
Email:
Affiliation:  Medtronic
Key inclusion & exclusion criteria

Inclusion Criteria:

- Subjects or appropriate legal guardians provide written informed consent and/or
authorization for access to and use of health information, as required by an
institution's IRB/MEC/REB.

AND one of the following must also apply:

- Subjects indicated for implant or within six months post-implant of a Medtronic
market-released lead connected to a Medtronic Adapta®, Sensia™, or Versa™ IPG. The
Medtronic lead must be used for pacing, sensing or defibrillation application.

- Subjects who participated in a qualifying study (IDE) of a Medtronic cardiac therapy
product and: 1) have a Medtronic Adapta®, Sensia™, or Versa™ IPG 2)product is
market-released 3) complete implant and follow-up data, including product-related
adverse events are available and 4) subject of appropriate legal guardian authorizes
release of subject study data to SLS

- Subjects implanted with a Medtronic Adapta®, Sensia™, or Versa™ IPG and Medtronic
CapSure Epi Leads (model 4965 and 4968) at a minimum of three pre-selected sites to
retrospectively collect data for post approval requirements.

Exclusion Criteria:

- Subjects who are, or will be inaccessible for follow-up at a SLS center

- Subjects with exclusion criteria required by local law (EMEA only)

- Subjects receiving an implant of a Medtronic device at a non-participating center and
the implant data and current status cannot be confirmed within 30 days after implant

- Subjects implanted with a Medtronic device whose predetermined enrollment limit for
that specific product has been exceeded



Age minimum: N/A
Age maximum: N/A
Gender: All
Health Condition(s) or Problem(s) studied
Bradycardia
Arrhythmia
Intervention(s)
Primary Outcome(s)
Rate of device malfunctions [Time Frame: 5 years]
Secondary Outcome(s)
Secondary ID(s)
nEw3 PAS
Source(s) of Monetary Support
Please refer to primary and secondary sponsors
Secondary Sponsor(s)
Ethics review
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history